| Q34541712 | AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology? |
| Q34592171 | African Burkitt lymphoma: Age-specific risk and correlations with malaria biomarkers |
| Q34189497 | Burkitt Lymphoma: Pathogenesis and Immune Evasion |
| Q33756475 | Burkitt lymphoma: epidemiological features and survival in a South African centre |
| Q33823095 | Burkitt's lymphoma masquerading as appendicitis--two case reports and review of the literature |
| Q38286857 | Cancer "causation" by infections--individual contributions and synergistic networks |
| Q36057221 | Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms |
| Q45362064 | Characterization of Epstein-Barr virus gp350/220 gene variants in virus isolates from gastric carcinoma and nasopharyngeal carcinoma |
| Q40382822 | Clinical and Epidemiological Characteristics of Burkitt Lymphomas in Pediatric Patients from Two Defined Socioeconomic Regions in Mexico |
| Q28742252 | Denis Burkitt and the African lymphoma |
| Q39220424 | Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature |
| Q33563969 | EBNA1 regulates cellular gene expression by binding cellular promoters |
| Q39633184 | EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide |
| Q34306768 | EBV, HCMV, HHV6, and HHV7 screening in bone marrow samples from children with acute lymphoblastic leukemia. |
| Q38273674 | Effect of HIV infection on the outcome of cancer therapy in children |
| Q59357734 | Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases |
| Q28068361 | Epigenetic Impact on EBV Associated B-Cell Lymphomagenesis |
| Q36001887 | Epigenetic mechanisms in virus-induced tumorigenesis |
| Q90481228 | Epstein Barr Virus Associated Lymphomas and Epithelia Cancers in Humans |
| Q44877602 | Epstein-Barr Virus Induces Adhesion Receptor CD226 (DNAM-1) Expression during Primary B-Cell Transformation into Lymphoblastoid Cell Lines. |
| Q35918250 | Epstein-Barr Virus Infection in Gastric Remnant Carcinoma and Recurrent Gastric Carcinoma in Qingdao of Northern China |
| Q36204326 | Epstein-Barr nuclear antigen 1 induces expression of the cellular microRNA hsa-miR-127 and impairing B-cell differentiation in EBV-infected memory B cells. New insights into the pathogenesis of Burkitt lymphoma |
| Q43410058 | Epstein-Barr virus gene polymorphism in different parts of the same nasopharyngeal carcinoma patient |
| Q98726287 | Epstein-Barr virus infection and genome polymorphisms on gastric remnant carcinoma: a meta-analysis |
| Q35166501 | Etiopathogenesis of Burkitt's lymphoma: a lesson from a BL-like in CD1 mouse immune to Plasmodium yoelii yoelii |
| Q55515337 | Frequency of EBV LMP-1 promoter and coding variations in burkitt lymphoma samples in Africa and South America and peripheral blood in uganda |
| Q64064157 | Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma |
| Q56889635 | HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data |
| Q37780706 | HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma |
| Q40750161 | Identification of IgH gene rearrangement and immunophenotype in an animal model of Epstein-Barr virus-associated lymphomas |
| Q36541271 | Immune Evasion by B-cell Lymphoma |
| Q38086861 | Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis |
| Q37309928 | Innate immune responses against Epstein Barr virus infection |
| Q56476000 | Interaction of viral oncogenic proteins with the Wnt signaling pathway |
| Q34138588 | Interleukin-6 and interleukin-10 gene promoter polymorphisms and risk of endemic Burkitt lymphoma |
| Q39016934 | Low expression of miR-150 in pediatric intestinal Burkitt lymphoma |
| Q37732974 | MYC in oncogenesis and as a target for cancer therapies |
| Q40123116 | Malaria, Epstein-Barr virus infection and the pathogenesis of Burkitt's lymphoma |
| Q37970680 | Molecular profiling of aggressive lymphomas |
| Q39556264 | PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells |
| Q40498690 | Parasites and cancer: is there a causal link? |
| Q36899190 | Parasites and malignancies, a review, with emphasis on digestive cancer induced by Cryptosporidium parvum (Alveolata: Apicomplexa). |
| Q34520470 | Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi |
| Q43092630 | Primary hepatic burkitt lymphoma presenting with acute liver failure |
| Q38822694 | Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines. |
| Q38406478 | Reprint of: cancer "causation" by infections--individual contributions and synergistic networks |
| Q40955418 | Sequence analysis of EBV immune evasion gene BNLF2a in EBV associated tumors and healthy individuals from nasopharyngeal carcinoma endemic and non-endemic regions of China. |
| Q35854314 | Sequence analysis of Epstein-Barr virus EBNA-2 gene coding amino acid 148-487 in nasopharyngeal and gastric carcinomas. |
| Q41675387 | Sequence variation of Epstein-Barr virus (EBV) BCRF1 in lymphomas in non-endemic areas of nasopharyngeal carcinoma |
| Q33743639 | Serum EBV antibodies and LMP-1 in Polish patients with oropharyngeal and laryngeal cancer |
| Q36262561 | Serum Metabolomics of Burkitt Lymphoma Mouse Models |
| Q42547317 | Specific tumor-stroma interactions of EBV-positive Burkitt's lymphoma cells in the chick chorioallantoic membrane |
| Q37733947 | The Epstein Barr-encoded BART-6-3p microRNA affects regulation of cell growth and immuno response in Burkitt lymphoma |
| Q92860015 | The Global Landscape of EBV-Associated Tumors |
| Q35945221 | The role of the tumor microenvironment in HIV-associated lymphomas |
| Q39548607 | Treatment of Akata EBV-positive cells with doxorubicin causes more EBV reactivation than treatment with etoposide |
| Q38090596 | Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery |
| Q45359052 | Unique variations of Epstein-Barr virus-encoded BARF1 gene in nasopharyngeal carcinoma biopsies |
| Q55263694 | Upregulation of the Chemokine Receptor CCR2B in Epstein‒Barr Virus-Positive Burkitt Lymphoma Cell Lines with the Latency III Program. |
| Q84957765 | Variations of Epstein-Barr virus nuclear antigen 1 gene in gastric carcinomas and nasopharyngeal carcinomas from Northern China |
| Q37681282 | Viral epigenomes in human tumorigenesis. |
| Q38296711 | Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas |